ACLY and Venous thrombosis: It must be noted that the patients enrolled in our study were at relatively low risk of recurrent thrombosis compared to many in the APS population—no patients had had previous failure of warfarin therapy, no patients were “triple positive,” and 20% of the study sample had only low-titer or one-time positive aCL or aβ2GP1.